Ortiz ROE

Idioma: Español
Referencias bibliográficas: 31
Paginas: 38-43
Archivo PDF: 128.48 Kb.

RESUMEN

La obesidad infantil se ha convertido en un problema de salud pública a nivel mundial y en la actualidad se considera una epidemia global. Su prevalencia continúa aumentando, siendo la enfermedad más frecuente en niños y adolescentes en países desarrollados. No es un problema estético, sino una enfermedad compleja que desencadena enfermedades cronicodegenerativas, que sólo veíamos en adultos. Nuestro país se ha convertido en el 2° lugar a nivel mundial de obesidad infantil. Es necesario tener más revisiones sistemáticas para causar impacto en profesionales de la salud y poder hacer intervenciones tempranas más efectivas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Reilly JJ. Obesity in childhood and adolescence: evidence based clinical and public health perspectives. Postgrad Med J 2006; 82: 429-37.

2. Troyano RP, Flegal KN. Overweight in children and adolescents. Description, epidemiology and demographics. Pediatrics 1998; 101: 497-504.

3. Brown M, Sibile K. Obesity in children and adolescents. Clin Family Practice 2002; 4(3): 1-14.

4. Must A. Effects of obesity on morbidity in children and adolescents. Nutr Clin Care 2003; 6(1): 4-12.

5. Ebbeling C, Pawiak D, Ludwig DS. Childhood obesity: public- health crisis, common sense cure. Lancet 2002; 360(9331): 473-82.

6. Sokol R. The chronic disease of childhood obesity: the sleeping giant has awakened. J Pediatr 2000; 136(6): 711-3.

7. Styne DM. Childhood and adolescent obesity. Prevalence and significance. Pediatr Clin North Am 2001; 48(4): 823-54.

8. Roberts SB, Savage J, Coward WA, Chew B, Lucas A. Energy expenditure and intake in infants born to lean and overweight mothers. N Engl J Med 1988; 318(1): 461-466.

9. Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, González-de Cossío T, Hernández-Prado B, Sepúlveda J. Encuesta Nacional de Nutrición 1999. Estado nutricio de niños y mujeres en México. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública, 2001.

10. Shamah-Levy T, Villalpando-Hernández S, Rivera-Dommarco JA. Resultados de Nutrición de la ENSANUT 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2007.

11. Nobili V, Manco M, Ciampalini P, Diciommo V, Devito R, Piemonte F et al. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol 2006; 155(5): 735-43.

12. Pombo AM. Tratado de endocrinología pediátrica. 3a ed. Madrid: Mc Graw-Hill. 2002.

13. Arya R, Duggirala R, Jenkinson C, Almasy L, Blangero J, O’Connell P et al. Evidence of a novel quantitative-trait locus for obesity on chromosome 4p in Mexican Americans. Am J Hum Genet 2004; 74: 272-282.

14. Yetman R. Evaluation and management of obesity in children and adolescents. J Pediatr Health Care 2004; 18(1): 35-8.

15. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116(7): 1802-12.

16. Li C, Ford ES, Mokdad AH, Cook SA. Recent trends in waist circumference and waist-height ratio among US children and adolescents. Pediatrics 2006; 118(5): e1390-8.

17. Sartorio A, Del Col A, Agosti F et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 2006; 61(7): 877-83.

18. Chiolero A, Madeleine G, Gabriel A, Burnier M, Paccaud F, Bovet P. Prevalence of elevated blood pressure and association with overweight in children of a rapidly developing country. J Hum Hypertens 2006; 21(2): 120-7.

19. Dessprés JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334(15): 952-7.

20. Burke V. Obesity in childhood and cardiovascular risk. Clin Exp Pharmacol Physiol 2006; 33(9): 831-7.

21. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104(23): 28 15-19.

22. Mantzoros CS, Flier JS. Insulin resistance: the clinical spectrum. Adv Endocrinol Metab 1995; 6: 193-232.

23. Wallace WJ, Sheslow D, Hassink S. Obesity in children: a risk for depression. Ann N Y Acad Sci 1993; 699: 301-3.

24. Gortmaker SL, Petersen K, Wiecha J, Sobol SM, Dixit S, Fix MK et al. Reducing obesity via a school-based interdisciplinary intervention among youth: Planet health. Arch Pediatr Adolesc Med 1999; 153: 409-18.

25. Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. Pediatrics 1998; 102(3): E29.

26. Epstein LH, Myers MD, Raynor HA et al. Treatment of pediatric obesity. Pediatr Adolesc Med 1998; 101(3pt2): 554-70.

27. Padwal R, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369(9555): 71-7.

28. Padwal R, Li SK, Lau DC. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0467 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55: 309.

29. Padwal RS, Li SK, Lau DC. Long term pharmacotherapy for obesity and overweight. Int J Obes Relat Metab Disord 2003; 27(12): 1437-46.

30. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56(6): 1093-124.

31. Curioni C, André C. Rimonabant for overweight for obesity. Cochrane Database Sys Rev 2006; 4: CD006162